St. Jude Medical Furthers the Company’s Legacy of Heart Valve Excellence With US Launch of the Trifecta Surgical Valve With...
May 16 2016 - 8:00AM
Business Wire
The new Trifecta™ Valve with Glide™ Technology offers improved
options for patients in need of aortic valve replacement through an
enhanced valve delivery designed to improve implantation
St. Jude Medical, Inc. (NYSE:STJ), a global medical device
company, today announced the U.S. launch of the company’s most
advanced tissue valve — the Trifecta™ valve with Glide™ Technology
(GT) — for the treatment of patients diagnosed with unhealthy,
damaged or malfunctioning aortic heart valves. Designed with
feedback from a cohort of international physicians, the Trifecta GT
tissue valve offers patients the benefit of enhanced valve delivery
to ease implantation in challenging anatomies and during minimally
invasive surgical approaches.
This Smart News Release features multimedia.
View the full release here:
http://www.businesswire.com/news/home/20160516005580/en/
The Trifecta™ Valve with Glide™
Technology (Photo: Business Wire)
The launch comes as St. Jude Medical celebrates its 40th
anniversary, affirming the company’s commitment to providing the
most advanced technology available to patients. To date, more than
3 million patients globally have received a St. Jude Medical™
valve. As the latest addition to the St. Jude Medical valve
portfolio, the Trifecta GT tissue valve continues the company’s
legacy of leadership and builds upon the proven best-in-class
hemodynamic (circulatory) excellence of the Trifecta™ tissue
valve.
“The new tissue valve offers enhancements that will only make
the implantation process smoother, providing a solution to patients
with even the most challenging of cases,” said Dr. Trey Pluscht, a
cardio-thoracic surgeon at Cardio-Thoracic and Vascular Surgical
Associates, P.C., of Alabama. “I welcome the opportunity to offer
patients the life-changing benefits we’ve come to expect from this
family of valves.”
Tissue aortic valve replacement can improve quality of life for
patients suffering from valve-related heart failure symptoms and
help patients with damaged or diseased native heart valves live
longer lives. The original Trifecta valve provided patients a
tissue valve that was proven to function in a similar way as their
native aortic valve. Now, the Trifecta GT tissue valve has improved
upon the original, and provides physicians a tissue valve option
that is easier to implant while retaining its optimal hemodynamic
performance.
Engineered to reduce wear and deterioration over time, the
Trifecta GT stented tissue valve offers improved tissue-to-tissue
contact when the leaflets open and close. Additionally, the valve
is treated with the St. Jude Medical™ Linx™ AC Treatment, an
anticalcification treatment designed to reduce tissue
mineralization (hardening). The valve’s fatigue-resistant titanium
stent provides a supportive frame within a patient’s heart for
added durability.
“Founded as a pioneering manufacturer of implantable bi-leaflet
mechanical heart valves, St. Jude Medical has dedicated significant
resources to develop best-in-class heart valve replacement options
while refining our devices based on physician feedback and clinical
outcomes,” said Dr. Mark Carlson, chief medical officer and vice
president of global medical affairs at St. Jude Medical. “The
Trifecta GT tissue valve is a true testament of our commitment to
the cardiac surgery community and the patients they treat by
improving the ability to implant the valve when encountering
challenging anatomies and during minimally invasive surgical
approaches.”
The Trifecta GT tissue valve received FDA approval in April
2016, further expanding the St. Jude Medical valve product
portfolio, which includes market-leading mechanical heart valves,
aortic and mitral tissue valves, valve repair annuloplasty rings
and the Portico™ TAVR valve available currently in Europe. The
Trifecta GT tissue valve is CE Mark approved and available in
Europe.
About St. Jude Medical
St. Jude Medical is a leading global medical device manufacturer
and is dedicated to transforming the treatment of some of the
world's most expensive epidemic diseases. The company does this by
developing cost-effective medical technologies that save and
improve lives of patients around the world. Headquartered in St.
Paul, Minn., St. Jude Medical employs approximately 18,000 people
worldwide and has five major areas of focus that include heart
failure, atrial fibrillation, neuromodulation, traditional cardiac
rhythm management and cardiovascular. For more information, please
visit sjm.com or follow us on Twitter @SJM_Media.
Forward-Looking Statements
This news release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995
that involve risks and uncertainties. Such forward-looking
statements include the expectations, plans and prospects for the
Company, including potential clinical successes, anticipated
regulatory approvals and future product launches, and projected
revenues, margins, earnings and market shares. The statements made
by the Company are based upon management’s current expectations and
are subject to certain risks and uncertainties that could cause
actual results to differ materially from those described in the
forward-looking statements. These risks and uncertainties include
market conditions and other factors beyond the Company’s control
and the risk factors and other cautionary statements described in
the Company’s filings with the SEC, including those described in
the Risk Factors and Cautionary Statements sections of the
Company’s Annual Report on Form 10-K for the fiscal year ended
January 2, 2016 and Quarterly Report on Form 10-Q for the fiscal
quarter ended April 2, 2016. The Company does not intend to update
these statements and undertakes no duty to any person to provide
any such update under any circumstance.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160516005580/en/
St. Jude Medical, Inc.Investor RelationsJ.C. Weigelt,
651-756-4347jweigelt@sjm.comorMedia RelationsLaurel Hood,
651-756-2853LHood02@sjm.com
SJM (NYSE:STJ)
Historical Stock Chart
From Mar 2024 to Apr 2024
SJM (NYSE:STJ)
Historical Stock Chart
From Apr 2023 to Apr 2024